Accessibility Menu
Cardiac Biotech Solutions logo

Cardiac Biotech Solutions(OTC) CBSC

Market Cap$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-98%
5 Year-89%
1 Year-28%
1 Month-14%
$0.03
+0%
+0.00Today
Cardiac Biotech Solutions last closing stock price
MetricPriceDate
Last closeUSD 0.032026-07-20
Cardiac Biotech Solutions stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.032026-07-08
1 month-14.26%USD 0.032026-06-18
3 month-25%USD 0.042026-04-20
Year to date-24.53%USD 0.042025-12-31
1 year-27.68%USD 0.042025-07-18
3 year-72.73%USD 0.112023-07-21
5 year-89.47%USD 0.292021-07-21
Since inception-97.65%USD 1.282015-12-11

Cardiac Biotech Solutions Financials at a Glance

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$152.73K

Net Income (TTM)

-$907.97K

EPS (TTM)

-$0.01

P/E Ratio

-5.45

Dividend

$0.00

Beta (Volatility)

0.13 (Low)

Price

$0.03

Volume

34,700

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.02 - $0.06

Estimated Earnings Date

Jun 29, 2026

CBSC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiac Biotech Solutions

Cardiac Biotech Solutions Inc. specializes in non-invasive, mobile cardiac monitoring solutions. The company offers a range of FDA and CE-approved EKG devices, cloud-based data acquisition software, and user-friendly smartphone applications.

Products and Services
  • FDA and CE-approved EKG devices for cardiac monitoring
  • Cloud-based software for data acquisition and analysis
  • Smartphone applications compatible with iOS and Android
Growth Outlook
  • Increasing demand for remote cardiac monitoring solutions
  • Expansion into international markets through subsidiaries
  • Focus on developing wearable ECG devices for extended use
Financial Highlights
  • Recent quarterly revenue of $40,460, showing consistent sales growth
  • Trailing twelve months (TTM) revenue of $150,000, indicating market traction
  • Operating expenses reflect investment in R&D and marketing efforts
Cardiac Biotech Solutions Inc. operates in the healthcare sector, focusing on innovative cardiac monitoring technologies. The company's products are designed to enhance patient engagement and provide healthcare professionals with accurate diagnostic insights. With a market capitalization of approximately $3.38 million, the company is positioned to capitalize on the growing demand for remote monitoring solutions, particularly in light of the increasing prevalence of heart-related conditions. The growth outlook is promising, driven by the expansion into international markets and the development of wearable ECG devices that allow patients to monitor their heart health over extended periods. Recent financial data indicates a steady revenue stream, with quarterly revenues showing a positive trend. The company's commitment to research and development is evident in its significant investment in R&D, which is crucial for maintaining a competitive edge in the rapidly evolving medical technology landscape. Overall, Cardiac Biotech Solutions Inc. presents an intriguing opportunity for investors interested in the healthcare technology sector, particularly in the realm of cardiac monitoring solutions.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

Charles K. Martin, III

Website

cardiacbiotech.com

Headquarters

Las Vegas, NV 92029, US

CBSC Financials

Key Financial Metrics (TTM)

Gross Margin

29.51%

Operating Margin

-757.45%

Net Income Margin

-594.50%

Return on Equity

42.18%

Return on Capital

N/A

Return on Assets

-183.77%

Earnings Yield

-18.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

165.44M

Volume

34.70K

Avg. Volume

12.29K

Financials (TTM)

Gross Profit

$45.07K

Operating Income

-$1.16M

EBITDA

-$1.16M

Operating Cash Flow

-$636.70K

Capital Expenditure

-$4.00

Free Cash Flow

-$636.70K

Cash & ST Invst.

$3.86K

Total Debt

$537.50K

Cardiac Biotech Solutions Performance Analysis

Cardiac Biotech Solutions annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 82,4059.0%
20242024-03-31USD 135,05563.9%
20252025-03-31USD 41,397-69.3%
20262026-03-31USD 152,729268.9%
Cardiac Biotech Solutions sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30557.4%
Q22025-09-30-40.4%
Q32025-12-3150.1%
Q42026-03-310.3%
Cardiac Biotech Solutions annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -0.02-74.5%
20242024-03-31USD -0.01-33.9%
20252025-03-31USD -0.01-9.4%
20262026-03-31USD -0.01-49.1%
Cardiac Biotech Solutions sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3052.0%
Q22025-09-30116.7%
Q32025-12-31-1850.0%
Q42026-03-3174.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$40.46K

+490.1%

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.24M

N/A

Employees

4

N/A

Net Income

-$103.05K

+74.1%

EBITDA

-$171.81K

+47.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$3.86K

-92.3%

Total Debt

$537.50K

+104.3%

Accounts Receivable

$88.37K

+1258.5%

Inventory

$160.75K

+476.4%

Long Term Debt

$0.00

N/A

Short Term Debt

$537.50K

+104.3%

Return on Assets

-1.84%

N/A

Return on Invested Capital

66.91%

N/A

Free Cash Flow

-$54.53K

+73.4%

Operating Cash Flow

-$54.53K

+73.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPIVFCaptiva Verde Wellness Corp.
$0.02+0.00%
RSCFReflect Scientific, Inc.
$0.04+0.00%
RMSLREMSleep Holdings, Inc.
$0.00-9.09%
TDSGFTelo Genomics Corp.
$0.03-3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About CBSC

What is the current price of Cardiac Biotech Solutions?

Cardiac Biotech Solutions is trading at $0.03 per share.

What is the 52-week range for Cardiac Biotech Solutions?

Over the past 52 weeks, Cardiac Biotech Solutions has traded between $0.02 and $0.06.

How much debt does Cardiac Biotech Solutions have?

As of the most recent reporting period, Cardiac Biotech Solutions reported total debt of $537.50K.

How much cash does Cardiac Biotech Solutions have on hand?

Cardiac Biotech Solutions reported $3.86K in cash and cash equivalents in its most recent financial results.

What is Cardiac Biotech Solutions’s dividend yield?

Cardiac Biotech Solutions does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services